SNGX vs. IBIO, NRBO, MEIP, SNSE, LUMO, KALA, VINC, SYBX, GLYC, and VBIV
Should you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include iBio (IBIO), NeuroBo Pharmaceuticals (NRBO), MEI Pharma (MEIP), Sensei Biotherapeutics (SNSE), Lumos Pharma (LUMO), KALA BIO (KALA), Vincerx Pharma (VINC), Synlogic (SYBX), GlycoMimetics (GLYC), and VBI Vaccines (VBIV). These companies are all part of the "pharmaceutical preparations" industry.
Soligenix (NASDAQ:SNGX) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.
3.6% of Soligenix shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.4% of Soligenix shares are held by insiders. Comparatively, 1.1% of iBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Soligenix has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, iBio has a beta of -3.22, meaning that its stock price is 422% less volatile than the S&P 500.
Soligenix presently has a consensus price target of $3.00, indicating a potential upside of 793.39%. iBio has a consensus price target of $5.00, indicating a potential upside of 114.59%. Given Soligenix's higher probable upside, equities research analysts plainly believe Soligenix is more favorable than iBio.
Soligenix received 277 more outperform votes than iBio when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 20.00% of users gave iBio an outperform vote.
In the previous week, Soligenix had 2 more articles in the media than iBio. MarketBeat recorded 6 mentions for Soligenix and 4 mentions for iBio. Soligenix's average media sentiment score of 0.66 beat iBio's score of 0.50 indicating that Soligenix is being referred to more favorably in the media.
iBio has a net margin of 0.00% compared to Soligenix's net margin of -1,025.66%. iBio's return on equity of -109.36% beat Soligenix's return on equity.
Soligenix has higher earnings, but lower revenue than iBio.
Summary
Soligenix beats iBio on 8 of the 15 factors compared between the two stocks.
Get Soligenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soligenix Competitors List
Related Companies and Tools
